Robert R Redfield

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. pmc Factors affecting job satisfaction and retention of medical laboratory professionals in seven countries of Sub-Saharan Africa
    Francesco Marinucci
    1Institute of Human Virology, University of Maryland School of Medicine, Baltimore 21201, USA
    Hum Resour Health 11:38. 2013
  2. pmc Clinical use of CCR5 inhibitors in HIV and beyond
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard St, Baltimore, 21201 Maryland, USA
    J Transl Med 9:S9. 2011
  3. pmc Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 105:20476-81. 2008
  4. ncbi request reprint CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 21:1317-22. 2007
  5. doi request reprint Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine
    Anthony Amoroso
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    HIV Clin Trials 10:320-3. 2009
  6. pmc Hepatitis C infection in HIV-1 natural viral suppressors
    Mohammad M Sajadi
    Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    AIDS 24:1689-95. 2010
  7. pmc Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland 21201, USA
    AIDS 25:1232-5. 2011
  8. doi request reprint Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Antiviral Res 83:86-9. 2009
  9. ncbi request reprint Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    AIDS 21:2108-10. 2007
  10. pmc Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells
    David J Riedel
    Division of Infectious Diseases, Institute of Human Virology, University of Maryland School of Medicine, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 23:1955-64. 2009

Collaborators

Detail Information

Publications30

  1. pmc Factors affecting job satisfaction and retention of medical laboratory professionals in seven countries of Sub-Saharan Africa
    Francesco Marinucci
    1Institute of Human Virology, University of Maryland School of Medicine, Baltimore 21201, USA
    Hum Resour Health 11:38. 2013
    ....
  2. pmc Clinical use of CCR5 inhibitors in HIV and beyond
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland School of Medicine, 725 West Lombard St, Baltimore, 21201 Maryland, USA
    J Transl Med 9:S9. 2011
    ..Their optimal use either alone or in combination with other agents will be defined by further investigation...
  3. pmc Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 105:20476-81. 2008
    ....
  4. ncbi request reprint CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Alonso Heredia
    Institute of Human Virology, University of Maryland, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 21:1317-22. 2007
    ..In the present study we evaluated the impact of differences in CCR5 levels among donor CD4 T cells on the infection efficiency and T-20 susceptibility of R5 HIV-1...
  5. doi request reprint Viral load decay in antiretroviral-naïve patients receiving once-daily tenofovir and emtricitabine plus twice-daily nevirapine
    Anthony Amoroso
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    HIV Clin Trials 10:320-3. 2009
    ..This study evaluated tenofovir and emtricitabine in combination with nevirapine...
  6. pmc Hepatitis C infection in HIV-1 natural viral suppressors
    Mohammad M Sajadi
    Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    AIDS 24:1689-95. 2010
    ..The objective of this study was to investigate whether HIV-infected NVSs also demonstrate enhanced ability to control hepatitis C virus (HCV) infection, and whether HCV infection in the NVSs affects the degree of HIV control...
  7. pmc Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, Maryland 21201, USA
    AIDS 25:1232-5. 2011
    ..These data, together with the high barrier of resistance to HGS004, suggest that combinations of maraviroc and HGS004 could provide effective preventive and therapeutic strategies against R5 HIV-1...
  8. doi request reprint Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Antiviral Res 83:86-9. 2009
    ..Combinations of RAPA and CCR5 antagonists could provide an effective means to control drug-resistant R5 HIV in patients, most notably those infected with Maraviroc-resistant viruses...
  9. ncbi request reprint Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland, USA
    AIDS 21:2108-10. 2007
    ..These results support further clinical evaluation of G1 cytostatic agents such as rapamycin targeting the downregulation of CCR5 expression as a strategy for both the prevention and treatment of HIV infection...
  10. pmc Natural viral suppressors of HIV-1 have a unique capacity to maintain gammadelta T cells
    David J Riedel
    Division of Infectious Diseases, Institute of Human Virology, University of Maryland School of Medicine, 725 W Lombard Street, Baltimore, MD 21201, USA
    AIDS 23:1955-64. 2009
    ..To evaluate Vgamma2Vdelta2 T cells in a group of HIV-infected patients who suppress HIV replication without antiretroviral therapy (natural viral suppressors, NVSs)...
  11. ncbi request reprint Tenofovir and abacavir combination therapy: lessons learned from an urban clinic population
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    AIDS Patient Care STDS 21:240-6. 2007
    ....
  12. pmc Rapamycin reduces CCR5 density levels on CD4 T cells, and this effect results in potentiation of enfuvirtide (T-20) against R5 strains of human immunodeficiency virus type 1 in vitro
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    Antimicrob Agents Chemother 51:2489-96. 2007
    ....
  13. pmc Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity
    Mohammad M Sajadi
    Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Acquir Immune Defic Syndr 57:9-15. 2011
    ..To examine the relationship between HIV-1 antigenic load (plasma RNA copies/mL) and broad HIV-1 neutralizing antibody activity...
  14. pmc Epidemiologic characteristics and natural history of HIV-1 natural viral suppressors
    Mohammad M Sajadi
    Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, MD, USA
    J Acquir Immune Defic Syndr 50:403-8. 2009
    ....
  15. ncbi request reprint Indirubin-3'-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication
    Alonso Heredia
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    AIDS 19:2087-95. 2005
    ..To evaluate the effects of the cyclin dependent kinase (CDK) inhibitor Indirubin-3'-monoxime (IM) on Tat-mediated transactivation function, a step of the HIV-1 cycle that is not currently targeted in antiviral therapy...
  16. pmc Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection
    Yongjun Guan
    Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 106:3952-7. 2009
    ..These data suggest that plasma Ab repertoires can underestimate the breadth of humoral immunity, and analyses of B(Mem) should be included in studies correlating Ab specificity with protective immunity to HIV-1...
  17. ncbi request reprint HIV-1 natural viral suppressors: control of viral replication in the absence of therapy
    Mohammad M Sajadi
    Institute of Human Virology, University of Maryland, Baltimore, Maryland, USA
    AIDS 21:517-9. 2007
    ..This ability to control HIV-1 viral replication naturally has led us to refer to them as natural viral suppressors...
  18. pmc IL28B genotype does not correlate with HIV control in African Americans
    Mohammad M Sajadi
    Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland, USA
    Clin Transl Sci 4:282-4. 2011
    ....
  19. pmc CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells
    Olga Latinovic
    Institute of Human Virology, University of Maryland School of Medicine, University of Maryland, Baltimore, MD 21201, USA
    Virology 411:32-40. 2011
    ..Thus, HGS004 and HGS101 have antiviral mechanisms distinct from 2D7 and could help overcome MVC resistance...
  20. doi request reprint Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection
    David J Riedel
    Division of Infectious Diseases and Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Lancet Infect Dis 8:261-7. 2008
    ..Infectious disease clinicians should be aware of this newly described and increasingly encountered lymphoma, since it is prominently associated with immunosuppression and may be mistaken for other entities...
  21. ncbi request reprint Approaches to antiretroviral therapy in China
    Bruce L Gilliam
    Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA
    Cell Res 15:895-902. 2005
    ..In the end, evidence based data supporting treatment strategies will allow China to successfully confront its AIDS epidemic early and prevent its tragic consequences...
  22. ncbi request reprint Commentary on "Prevalence and evolution of drug resistance HIV-1 variants in Henan, China"
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland, Baltimore, MD 21201, USA
    Cell Res 15:850-1. 2005
  23. ncbi request reprint Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    AIDS Patient Care STDS 20:745-59. 2006
    ..Further studies of ATV + LPV/r in HIV-treatment are warranted...
  24. ncbi request reprint In vitro suppression of latent HIV-1 activation by vitamin E: potential clinical implications
    Alonso Heredia
    Division of Clinical Research, Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, MD, USA
    AIDS 19:836-7. 2005
    ..0015). These results suggest that vitamin E supplementation may interfere with the emergence of drug-resistant HIV-1 variants archived in the resting cell reservoir and delay or limit virus rebound upon treatment interruptions...
  25. ncbi request reprint Improving on success: what treating the urban poor in America can teach us about improving antiretroviral programmes in Africa
    Anthony Amoroso
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
    AIDS 18:S39-43. 2004
    ..New treatment delivery programmes designed to address these concerns for the urban poor in the USA may represent models that can achieve high levels of treatment success in resource-limited countries...
  26. ncbi request reprint Acute renal failure and nephrotic range proteinuria due to amyloidosis in an HIV-infected patient
    Kirk M Chan-Tack
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Am J Med Sci 332:364-7. 2006
    ..Clinical diagnosis, based on CD4 count, viral load, and degree of proteinuria, may not predict the pathological diagnosis in HIV-positive patients...
  27. pmc Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein
    Tracy J Ruckwardt
    Institute of Human Virology, University of Maryland Biotechnology Institute, 725 W Lombard St, Room N546, Baltimore, MD 21201, USA
    J Virol 78:13190-6. 2004
    ..Tat-neutralizing antibodies to the dominant amino terminus epitope are affected by HIV clade variation...
  28. pmc Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned
    Ronald B Reisler
    Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    J Acquir Immune Defic Syndr 39:159-66. 2005
    ..To report on the incidence of clinical- and laboratory-defined pancreatitis in HIV-1-infected individuals treated with antiretrovirals (ARVs)...
  29. ncbi request reprint Association between longer duration of HIV-suppressive therapy and partial recovery of the V gamma 2 T cell receptor repertoire
    Jose Bordon
    Institute of Human Virology, University of Maryland Biotechnology Institute, Baltimore, Maryland 21201, USA
    J Infect Dis 189:1482-6. 2004
    ..Changes in the V gamma 2 TCR repertoire are sensitive measures for the effects of HAART and of residual HIV replication...
  30. ncbi request reprint Therapeutic HIV vaccines
    Bruce L Gilliam
    Institute of Human Virology, University of Maryland, 725 West Lombard Street, Baltimore, MD 21201, USA
    Curr Top Med Chem 3:1536-53. 2003
    ..Yet even more notable, is that, if successful, a therapeutic vaccine product would be inexpensive and rapidly exportable representing a treatment strategy for people living with HIV infection worldwide...